ArticleAnnals of medicine and surgery (2012)2025

Hope on the horizon: FDA approves eplontersen for hereditary transthyretin-mediated amyloidosis.

Insa Binte Anwar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.